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We performed the Tottori-Kofu Study to develop an early detection method of the Japa-
nese with diabetes mellitus (DM) and impaired glucose tolerance (IGT), using simple pre-
dictors such as fasting plasma glucose (FPG) and other risk information obtainable from 
basic medical check-ups. In 2005, 734 residents of Kofu Town received a basic medical 
check-up including blood examination.  Some of them meeting the following criteria fur-
ther underwent the oral glucose tolerance test (OGTT):  5.5 mmol/L (100 mg/dL) ≤ FPG < 
7.0 mmol/L (126 mg/dL); or FPG < 5.5 mmol/L, HbA1c ≥ 5.5%, BMI ≥ 25 kg/m2, triglycer-
ide ≥ 1.69 mmol/L (150 mg/dL), hypertension treatment and family history of DM.  Among 
the 734, only 4 persons with FPG ≥ 7.0 mmol/L were newly diagnosed as having DM, and 
17 persons with FPG ≥ 6.1 mmol/L (110 mg/dL) were diagnosed with impaired fasting glu-
cose.  Among 220 persons who received the OGTT, 115 had normal glucose tolerance, 85 
had IGT and 20 had DM.  When the above-mentioned criteria were added to FPG levels, 
additional 67 persons with abnormal glucose tolerance were found.  The optimal level to 
detect IGT and DM was 5.2 mmol/L (93 mg/dL) for FPG and 5.3% for HbA1c.  Of persons 
only with the single risk factor of hypertension treatment, 39.3% had IGT.  In conclusion, 
the results indicate that FPG of 5.2 mmol/L (93 mg/dL), HbA1c of 5.3% and hypertension 
treatment are useful in detecting early stages of IGT and DM. 
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Atherosclerotic diseases such as heart disease and 
cerebral stroke are increasing in Japan with the 
aging of population in Japan and with changes of 
lifestyle.  It is necessary to elucidate risk factors 
and to establish a useful and cost-benefit method 
to prevent the onset of diabetes mellitus (DM) and 
impaired glucose tolerance (IGT).  The American 
Diabetes Association proposed new criteria for 
the diagnosis of diabetes (1997).  The Associa-
tion recommended the diagnosis of diabetes with 
the fasting plasma glucose (FPG) levels and not 
with the oral glucose tolerance test (OGTT) in a 
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clinical setting, from the viewpoint of cost and 
convenience (Expert Committee on the Diagno-
sis and Classification of Diabetes Mellitus, 1997). 
The use of OGTT is still emphasized for clinical 
diagnosis of IGT and DM in Japan.  In 1999, the 
Japan Diabetes Society published new diagnostic 
criteria of diabetes, and had left the OGTT as a 
method of diagnosis (Kuzuya et al., 2002).  The use 
of OGTT stems from the fact that the pathology of 
diabetes in Asians including the Japanese does not 
arise mainly from obesity and insulin resistance, 
as in Europeans and Americans.  In Japan, half of 
diabetics have a genetic background, and in lean 
persons, insulin secretion is impaired.  Therefore, it 
is difficult to detect diabetes in its early stages with 
the FPG level alone (Kadowaki et al., 1984, 1994). 
The DECODA Study showed that 45% of diabetics 
were missed when the OGTT was not performed 
(Qiao et al., 2000).  Therefore, the World Health 
Organization (WHO) also has recommended the 
OGTT as a screening for diabetes (Alberti et al., 
1998).  We think it important to develop a screen-
ing protocol for persons at high risk of diabetes by 
using a combination of FPG and HbA1c because of 
its simplicity. 
 The criteria for glucose intolerance in the ba-
sic health examination of residents are established 
in the Law of Health and Medical Service for the 
Aged in Japan.  The criteria recommend that medi-
cal treatment is necessary in persons with FPG ≥ 7.0 
mmol/L (126 mg/dL), casual plasma glucose ≥ 11.1 
mmol/L (200 mg/dL) and HbA1c ≥ 6.1%.  How-
ever, if the test results are the following, the patient 
will need lifestyle guidance and will not require 
the intensive examination at a medical institu-
tion:  6.1 mmol/L (110 mg/dL) ≤ FPG < 7.0 mmol/
L (126 mg/dL), 7.8 mmol/L (140 mg/dL) ≤ casual 
plasma glucose < 11.1 mmol/L (200 mg/dL), 5.5% 
≤ HbA1c < 6.1%.  The persons with the following 
results will be considered to have no abnormality: 
FPG < 6.1 mmol/L (110 mg/dL), casual plasma glu-
cose < 7.8 mmol/L (140 mg/dL) and HbA1c < 5.5%. 
There have been reports that the following criteria 
have high sensitivity to detect diabetes in Japanese: 
FPG ≥7.0 mmol/L (126 mg/dL) and HbA1c ≥ 6.1% 
(Takahashi et al., 2000; Ito et al., 2000).  However, 
it has been reported that a plasma glucose level of 
11.1 mmol/L (200 mg/dL) at 2 h after glucose load (2 
h-LPG) was equivalent to FPG level of 5.8 mmol/
L (104 mg/dL) in Asians (Nakagami et al., 2002). 
Moreover, in 2003, the American Diabetes Associ-
ation indicated that the cutoff level for IFG should 
be reduced from 110 to 100 mg/dL, and that IFG 
should be redefined as an FPG of 100 to 125 mg/
dL (5.6–6.9 mmol/L) (The Expert Committee on 
the Diagnosis and Classification of Diabetes Mel-
litus, 2003).  Although the criteria described above 
appear to be sensitive enough to detect apparent 
diabetes, persons with early stage diabetes or IGT 
may be missed. 
 Kofu Town is located near the Tottori Univer-
sity Faculty of Medicine.  The residents of Kofu 
Town have suffered from a 3-fold higher incidence 
of cerebral stroke than the national average in Japan. 
In order to prevent cerebral stroke events, a new 
program called the Tottori-Kofu Study was started 
in 2005.  The program intends to detect high-risk 
persons for cerebral stroke and recruit them into 
early intervention protocols such as lifestyle guid-
ance.  Within the program, we tried to develop an 
effective screening method for IGT or DM, since 
IGT or DM are recognized as high-risk factors for 
stroke.  The aim of this study is to develop an effec-
tive and low-cost strategy for early detection of DM 
and IGT.  This strategy utilized simple predictors 
including FPG, HbA1c and body mass index (BMI) 
from the basic examination results.
 
Subjects and Methods
 
Research design and subjects
 
This is a cross-sectional study.  The subjects were 
734 residents aged 35 years or older who had un-
dergone a basic medical check-up in 2005 in Kofu 
Town, Tottori Prefecture, Japan (Fig. 1).
Confirmation of risk factors
 
At the basic medical check-up for the 734 resi-
dents, height, weight and blood pressure (BP) were 
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measured.  Blood was also collected and plasma 
glucose, HbA1c and serum triglyceride levels were 
measured.  Plasma glucose was measured with the 
glucose oxidase method, and HbA1c by high-per-
formance liquid chromatography.  The BMI [body 
weight (kg)/height2 (m2)] and serum triglyceride 
levels were used to determine whether or not the 
persons were overweight (BMI ≥ 25 kg/m2:  high-
BMI) or hypertriglyceridemic [triglyceride ≥ 1.69 
mmol/L (150 mg/dL):  high-triglyceride].  In addi-
tion, the following history was confirmed:  history 
of hypertension treatment and family history of 
diabetes in relatives within 3 degrees of kinship. 
 To establish the risk criteria for this study, we 
referred to past reports in the literature.  One of the 
reports examined plasma glucose and HbA1c of an-
other Asians, Chinese subjects.  It stated that FPG 
≥ 5.6 mmol/L (104 mg/dL) and HbA1c ≥ 5.5% were 
the most sensitive and specific (Ko et al., 1998).  In 
Japanese persons, the risk of DM for those under 
60 years of age and with BMI ≥ 25 kg/m2 is 50% 
higher than for those who do not meet these condi-
tions (Ito et al., 1994).  When factors related to 2 
h-LPG were examined, the profiles of age, BMI, 
triglyceride and hypertension were considered to 
be predictors for 2 h-LPG (Bando et al., 2001).  Ac-
cording to the DECODE (DECODE Study Group, 
2003), DECODA (Nakagami and DECODA 
Study Group, 2004), Hisayama (Fujishima et al., 
1996) and Funagata (Tominaga et al., 1999) Stud-
ies, the risk of a cardiovascular event in IGT was 
approximately 2 times higher than in the normal 
type.  The Third National Health and Nutrition 
Examination Survey in the United States indicated 
that the IGT risk is high in those with risks such 
as FPG ≥ 5.5 mmol/L (100 mg/dL), age of 64 to 
74 years, triglyceride ≥ 1.69 mmol/L (150 mg/dL), 
BMI ≥ 30 kg/m2 and hypertension (Nelson et al., 
2003). Moreover, another Japanese study reported 
that the familial history for hypertension, diabetes 
and dyslipidemia is an important aid towards a 
prevention strategy and public health practice for 
metabolic disorders (Wada et al., 2006). Based on 
the previous reports, we applied the OGTT for our 
subjects who had a risk of 5.5 mmol/L (100 mg/
dL) ≤ FPG < 7.0 mmol/L (126 mg/dL); or who had 
FPG < 5.5 mmol/L but had HbA1c ≥ 5.5%, BMI 
≥ 25 kg/m2, triglyceride ≥ 1.69 mmol/L (150 mg/
dL), hypertension treatment or family history of 
DM.  The number of high-risk residents of the lat-
ter group was 350.  However, diabetics with FPG 
< 5.5 mmol/L and HbA1c < 5.5% are rare, as re-
ported in Chinese and Japanese population studies 
as only 2% of these participants was DM (Ko et al., 
1998; Takahashi et al., 2001).  When the BMI was 
less than 25, 24.9% of the sample population was 
diabetic (Ito, 1983). When the triglyceride level was 
less than 150 mg/dL, 4% of the sample population 
FPG dose equivalence:  
  5.5 mmol/L to 100 mg/dL
 6.1 mmol/L to 110 mg/dL
 7.0 mmol/L to 126 mg/dL
*Other risk factors: 
  BMI ≥ 25 kg/m2 
 Triglyceride ≥ 150 mg/dL
 Hypertension treatment 
 Familial history of DM 
Fig. 1.  Cross-sectional study design for the Tottori-Kofu Study.  BMI, body mass index; DM, diabetes mellitus; FPG, fast-
ing plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test. 
734 persons, FPG measured
 32 persons, DM treatment
   4 persons, DM (FPG ≥ 7.0 mmol/L) 
698 persons, not diagnosed as having DM
 348 persons with FPG < 5.5 mmol/L, HbA1c < 5.5% and no other risk factors*
350 persons with FPG ≥ 5.5 mmol/L, HbA1c ≥ 5.5% and other risk factors*, 
 requested to take OGTT
 130 persons did not accept OGTT 
220 persons received OGTT
  53 persons:  5.5 mmol/L ≤ FGP < 7.0 mmol/L  27 IGT and 11 DM persons
167 persons:  FPG < 5.5 mmol/L with other risk factors  58 IGT and  9 DM persons
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was diabetic (Kametani et al., 2002).  According 
to these studies, in participants with FPG < 5.5 
mmol/L, HbA1c < 5.5%, BMI < 25 kg/m2 and trig-
lyceride < 1.69 mmol/L, the percentage of DM was 
calculated as 2% by 25% by 4%, resulting as 0.02%. 
So, we did not apply the OGTT to the 348 residents 
with FPG < 5.5 mmol/L, HbA1c < 5.5%, BMI < 
25kg/m2, triglyceride < 1.69 mmol/L, with no fam-
ily history of DM or with no hypertension treat-
ment.  Finally, the OGTT was performed on 220 
residents of the 350, the remaining 130 refusing the 
test.  However, there was no significant difference 
between the 220 performed and 130 nonperformed 
residents according to age, BMI, FPG, HbA1c, trig-
lyceride level, SBP and DPB (unpaired t-test, data 
not shown).
 Measurement of waist circumference is not 
included in a routine medical check-up under the 
Health and Medical Service Law for the Aged.  But 
in this study, we decided to measure waist circum-
ference to estimate the clinical relevance of waist 
abnormality.  The diagnostic criteria of metabolic 
syndrome in Japan were applied to determine the 
abnormal waist circumference sizes as ≥ 85 cm for 
males and ≥ 90 cm for females (Examination Com-
mittee of Criteria for ‘Obesity Disease’ in Japan, 
2002).
 
Determination of abnormal glucose tolerance
 
As a secondary screening test, the 75-g OGTT 
was used for persons who accepted to take the test. 
The determination of diabetes was based on the 
1998 diagnostic criteria of the WHO and with the 
levels of FPG and 2 h-LPG (Alberti et al., 1998). 
The subjects were determined to have DM if they 
had FPG ≥ 7.0 mmol/L (126 mg/dL) or 2 h-LPG ≥ 
11.1 mmol/L (200 mg/dL).  The subjects were de-
termined to have IGT if they had FPG < 7.0 mmol/
L (126 mg/dL) and 7.8 mmol/L (140 mg/dL) ≤ 2 
h-LPG < 11.1 mmol/L (200 mg/dL).  The subjects 
were determined to have impaired fasting glucose 
(IFG) if they had 6.1 mmol/L (110 mg/dL) ≤ FPG < 
7.0 mmol/L (126 mg/dL) and 2 h-LPG < 7.8 mmol/
L (140 mg/dL).  Even if the subjects were normal 
based on the WHO criteria, if a Japanese has 1 
h-LPG ≥ 10.0 mmol/L (180 mg/dL), the risk of 
developing diabetes is higher than those having 1 
h-LPG < 10.0 mmol/L.  The persons with 1 h-LPG 
≥ 10.0 mmol/L should be handled as with IGT ac-
cordingly (Kuzuya et al., 2002).  In a recent report, 
the cutoff value for impaired glucose regulation 
was 10.1 mmol/L (182 mg/dL) for blood glucose 
at 60 min (Zhou et al., 2006a, 2006b).  One study 
from the United States indicates that a high level 
of plasma glucose at 30 to 90 min is associated 
with increased cardiovascular risk factors, even in 
groups with normal FPG and 2 h-LPG (Modan et 
al., 1989).  Therefore, persons with 1 h-LPG ≥ 10.0 
mmol/L (180 mg/dL) were determined to have IGT. 
Persons not classified into either group were deter-
mined to have normal glucose tolerance:  their FPG 
was < 6.1 mmol/L (110 mg/dL), 1 h-LPG < 10.0 
mmol/L (180 mg/dL) and 2 h-LPG < 7.8 mmol/L 
(140 mg/dL). 
 
Statistical analysis
 
Data were expressed as mean ± SEM.  Significance 
of differences in mean values was determined by 
using unpaired t-tests.  In the logistic regression 
analysis, the persons determined to have IGT and 
DM were combined as persons with abnormal glu-
cose tolerance (IGT + DM).  The dependent vari-
able was abnormal glucose tolerance (IGT + DM), 
and the explanatory variables were male, HbA1c 
≥ 5.5%, high-BMI, high-triglyceride, hypertension 
treatment, family history of diabetes, family histo-
ry of hypertension, waist abnormality and age.  Bi-
nomial logistic regression was performed, and the 
factors with significant odds ratios were obtained. 
Odds ratios were determined if the explanatory 
variables were redundant.  A P value, 0.05 or less, 
was considered to be statistically significant. 
 To evaluate the DM + IGT, we determined 
the cutoff values from the receiver operating char-
acteristic (ROC) analysis of the optimal FPG and 
HbA1c.  The sensitivity of FPG and HbA1c cutoff 
points on the results of the basic medical check-
up was defined as its ability to correctly identify 
persons who had abnormal glucose tolerance (IGT 
or DM) in the OGTT.  The specificity was defined 
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as its ability to correctly identify persons who had 
NGT in the OGTT.  To compare the ability of FPG 
and HbA1c measurements to detect the presence 
or absence of abnormal glucose tolerance (IGT 
or DM), we plotted ROC curves.  The diagnostic 
properties of specific cutoff levels of FPG and 
HbA1c were defined by maximizing the sensitivity 
and specificity to identify IGT or DM.  An ROC 
curve is a graph of sensitivity versus (1 – speci-
ficity) for various cutoff definitions of a positive 
diagnostic test result.  The optimal cutoff points 
were obtained from the Youden index [maximum 
(sensitivity + specificity – 1)], and the point on the 
ROC curve closest to (0,1) was calculated as the 
minimum value of the square root of [(1 – sensitiv-
ity)2 + (1 – specificity)2] (Youden, 1950; Perkins et 
al., 2006).  Greater accuracy is reflected by a larger 
Youden index and a smaller distance to (0, 1).  SPSS 
15.0 (SPSS, Chicago, IL) was used for analysis.
 
 
Results
 
The present 734 subjects consisted of 272 males 
and 462 females.  Their mean age was 66.4 years, 
mean BMI 22.7 kg/m2, mean FPG 5.07 mmol/L 
(91.4 mg/d L), mean HbA1c 5.19%, mean systolic 
BP 127.8 mmHg, mean diastolic BP 76.0 mmHg 
and mean fasting triglyceride 1.16 mmol/L (103.5 
mg/dL) (Table 1).  From the 734, 32 persons who 
had already been treated for diabetes were ex-
cluded.  Of the 702 not treated for diabetes, only 4 
persons with FPG ≥ 7.0 mmol/L (126 mg/dL) were 
newly diagnosed as having diabetes and only 17 
persons with 6.1 mmol/L (110 mg/dL) ≤ FPG < 7.0 
mmol/L, as having IFG (Table 2).  As described in 
the Subjects and Methods, a total of 220 persons 
accepted the OGTT as the secondary examination. 
 In the results of the OGTT for the 220 per-
sons, mean BMI was 23.9 kg/m2, mean FPG, 5.17 
mmol/L (93.0 mg/dL) and mean HbA1c, 5.20% 
(Table 1).  Mean levels in BMI, systolic BP, diastol-
ic BP and triglyceride were significantly higher in 
the OGTT-received persons than the basic medical 
checked-up, but those in FPG and HbA1c were not. 
Among the OGTT-received persons, 115 (52.3%) 
had normal glucose tolerance, 85 (38.6%) had IGT 
and 20 (9.1%) had DM (Table 2).  No person had 
IFG.  Among 14 persons with 6.1 mmol/L (110 mg/
dL) ≤ FPG < 7.0 mmol/L (126 mg/dL), 5 persons 
(35.7%) had IGT and 7 persons (50%) had DM. 
Two persons showed normal glucose tolerance 
Table 1.  Clinical characteristics of persons who received the basic medical check-up and the sec-
ondary OGTT 
 
 Persons who received P value
 The basic medical check-up The OGTT 
 
Number of persons 734 220
Male/female ratio 272/462 82/138
Age (year) 66.4 ± 13.0 66.5 ±  11.4 NS
Height (cm) 155.6  ± 8.5 154.8 ±  8.2 NS
Weight (kg) 55.1 ±  10.3 57.4  ±  10.0 < 0.005
Body mass index (kg/m2) 22.7  ± 3.5 23.9  ±  3.2 < 0.005
FPG (mmol/L) 5.07  ± 0.67 5.17  ±  0.53 NS
HbA1c (%) 5.19  ± 0.4 5.20  ±  0.3 NS
Systolic BP (mmHg) 127.8  ± 17.8 133.8  ±  16.8 < 0.005
Diastolic BP (mmHg) 76.0  ± 10.6 79.0  ±  9.2 < 0.005
Total cholesterol (mmol/L) 5.27  ± 0.84 5.37  ±  0.83 NS
Triglyceride (mmol/L) 1.16  ± 0.67 1.42  ±  0.82 < 0.005
HDL-cholesterol (mmol/L) 1.49  ± 0.35 1.40  ±  0.33 < 0.005
 
Data represent mean ± SD. 
P values represent results of comparison between groups of persons receiving the basic check-up and the secondary OGTT. 
Unpaired t-test was used for statistical analysis.
BP, blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; NS, not significant; OGTT, oral glucose tol-
erance test.
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with FPG < 6.1 mmol/L (110 mg/dL) in the OGTT 
in spite of their FPG ≥ 6.1 mmol/L in the basic 
medical check-up.  Among the 39 persons with 5.5 
mmol/L (100 mg/dL) ≤ FPG < 6.1 mmol/L (110 
mg/dL), 22 persons (56.4%) had IGT and 4 persons 
(10.3%) had DM.  Among 167 persons with FPG < 
5.5 mmol/L (100 mg/dL) with other risk factors, 58 
persons (34.7%) had IGT and 9 persons (5.3%) had 
DM.
 In analyzing persons with FPG < 5.5 mmol/
L (100 mg/dL) and with another single risk fac-
tor (Table 3), persons with a single risk factor of 
HbA1c ≥ 5.5% were accounted for 22, who includ-
ed 12 IGT persons (54.6%) and 6 DM persons (27%). 
Persons with a single risk factor of high-BMI were 
accounted for 33, who included 9 IGT persons 
(27.3%).  Those with a single risk factor of high-
triglyceride were 16, including 1 IGT person (6.3%) 
and 1 DM person (6.3%).  Those with a single risk 
factor of hypertension treatment were 61, including 
24 IGT persons (39.3%).  Those with a single risk 
factor of family history of DM were 7, including 2 
IGT persons (28%).  Therefore, of all 220 persons 
who received the OGTT, a total number of persons 
Table 2.  Results of OGTT classified by FPG levels and other factors
 
           FPG level  Persons who received  Results of the OGTT
  in the basic medical  The basic medical  The Normal  Abnormal
            check-up  check-up OGTT (NGT) IGT DM IGT + DM
 
DM treatment (+) 32
7.0 mmol/L ≤ FPG 4
6.1 mmol/L ≤ FPG < 7.0 mmol/L  17 14 2 (14.3) 5 (35.7)  7 (50.0)  12 (85.7)
5.5 mmol/L ≤ FPG < 6.1 mmol/L  60 39 13 (33.3)  22 (56.4)  4 (10.3) 26 (66.7)
FPG < 5.5 mmol/L with other risk factors 238 167 100 (59.8)  58 (34.7) 9 (  5.3)  67 (40.1)
FPG < 5.5 mmol/L and HbA1c < 5.5% 
   with no other risk factors 348
Total 734 220 115 (52.3)  85 (38.6)  20 (  9.1)  105 (47.7)
 
FPG dose equivalence:  5.5 mmol/L equivalent to 100 mg/dL; 6.1 mmol/L, to 110 mg/dL; 7.0 mmol/L, to 126 mg/dL.
Data represent number of persons:  (   ), %.  
No one with impaired fasting glucose.
DM, diabetes mellitus; FPG, fasting plasma glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; 
OGGT, oral glucose tolerance test.
Table 3.  Results of the OGTT in persons with FPG < 5.5 mmol/L and other risk factors
  Risk factor Results of the OGTT
HbA1c  BMI Triglyceride Hyper-  Familial Number Normal  Abnormal
≥ 5.5  ≥ 25   ≥ 1.69  tension history of (NGT) IGT DM IGT + DM
 kg/m2 mmol/L   treatment of DM persons 
 
 + + or – + or – + or –  + or – 22 4 ( 18.2) 12 (54.6) 6 (27.3)  18 (81.8)
 –  +  –   –   + or –   33   24 ( 72.7) 9 (27.3) 0 (  0   )  9 (27.3)
 –  –   +   –   + or –   16   14 ( 87.5)  1 (  6.3)  1 (  6.3)  2 (12.6)
 –   –   –   +   + or –   61   37 ( 60.7)  24 (39.3) 0 (  0   )  24 (39.3)
 –   +  +   –   + or –   14   7 ( 50.0) 6 (42.8)  1 (  7.1)  7 (50.0)
 –   +    –   +   + or –   4   2 ( 50.0) 2 (50.0)  0 (  0   )  2 (50.0)
 –  –   +   +   + or –   5   2 ( 40.0)  2 (40.0)  1 (20.0)  3 (60.0)
 –   +   +   +   + or –   5   5 (100  ) 0 (  0  )  0 (  0   )  0 (  0)
 –   –   –  –   +   7   5 ( 71.4)  2 (28.6)  0 (  0   )  2 (28.6)
 
Subtotal in FPG < 5.5 mmol/L with other risk factors 167  100 ( 59.8) 58 (34.7)  9 (  5.3)  67 (40.1)
 
FPG dose equivalence:  5.5 mmol/L equivalent to 100 mg/dL.
Data represent number of persons: (  ), %. 
BMI, body mass index; DM, diabetes mellitus; FPG, fasting plasma glucose; IGT, impaired glucose tolerance; NGT, normal 
glucose tolerance; OGGT, oral glucose tolerance test.
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with glucose intolerance was 105 (47.7%).  When 
the above-mentioned criteria were added to FPG 
for the 220, additional 67 abnormal persons were 
detected (Table 3). 
 Logistic analysis was applied to statistically 
examine the risk factors for abnormal glucose tol-
erance (DM + IGT).  For abnormal glucose toler-
ance (DM + IGT), the odds ratio of hypertension 
treatment was 2.43 (P = 0.077; 95% confidence 
interval, 0.91–6.49) and that of familial history of 
DM was 2.64 (P = 0.094; 95% confidence interval, 
0.85–8.23), indicating a weak tendency, respec-
tively (Table 4).  We also examined the criteria of 
the abnormal waist size as ≥ 85 cm for males and ≥ 
90 cm for females, but the abnormal waist size was 
not a significant risk factor.  Next, we determined 
FPG with the highest sensitivity and specificity us-
ing the ROC curve for abnormal glucose tolerance 
(DM + IGT).  The optimal FPG was 5.2 mmol/L (93 
mg/dL) (sensitivity, 0.62 and specificity, 0.65) (Fig. 
2a), and the optimal HbA1c, 5.3% (sensitivity, 0.57 
and specificity, 0.74) (Fig. 2b).
 
Discussion
 
In this study, the Government-driven criteria were 
specific to detect relevant IGT and DM; however, 
it was not sufficient for early detection of mild 
DM and IGT.  When a condition such as high-
triglyceride or hypertension treatment was added 
to Government-driven FPG and HbA1c criteria, we 
could detect many people with abnormal glucose 
tolerance. 
 The optimal HbA1c to detect the IGT + DM 
pattern in the ROC analysis was 5.3%:  this result 
was compatible with other studies in Asians (Na-
kagami et al., 2002).  However, the optimal FPG 
we observed to detect IGT + DM was 5.2 mmol/
L (93 mg/dL).  Our sample population was much 
smaller than that of the DECODA Study.  Recently, 
the High-risk and Population Strategy for Occu-
pational Health Promotion Study reported that the 
risk of diabetes abruptly rose in persons with blood 
glucose levels higher than 5.2 mmol/L (94 mg/dL) 
(Hayashino et al., 2007).  We consider that FPG 5.2 
Table 4.  Odds ratio for IGT + DM by multiple re-
gression analysis
 
              Risk factor Abnormal glucose tolerance
 (IGT + DM)
 Odds P 95%
  ratio value Confidence 
   interval
 
Age 0.99 0.618 0.96–1.02
Gender (male) 1.10 0.803 0.50–2.45
BMI ≥ 25.0 kg/m2 1.70 0.294 0.63–4.55
Triglyceride ≥ 1.69 mmol/L 0.95 0.899 0.40–2.23
Hypertension treatment 2.43 0.077 0.91–6.49
HbA1c ≥ 5.5% 16.3 0.001 4.09–65.8
Familial history of DM 2.64 0.094 0.85–8.23
Familial history of hypertension 1.29 0.532 0.58–2.84
Waist abnormality 1.32 0.558 0.52–3.39
 
Data are the dependent variable (abnormal glucose toler-
ance) versus the explanatory variable (NGT):  abnormal 
glucose tolerance,  DM in 20 and IGT in 85 persons; NGT in 
115 persons. 
Adjusted for all explanatory variables. 
BMI, body mass index; DM, diabetes mellitus; IGT, im-
paired glucose tolerance; NGT, normal glucose tolerance.
Fig. 2.  Receiver operating characteristic curves for FPG 
and HbA1c in predicting DM + IGT in the OGTT.  Sen-
sitivity is plotted as a function of (1 – specificity). Points 
on the curve representing optimal FPG and HbA1c are 
marked with circles.  DM, diabetes mellitus; FPG, fasting 
plasma glucose; IGT, impaired glucose tolerance; OGTT, 
oral glucose tolerance test.
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mmol/L and HbA1c 5.3% were effective to detect 
IGT and DM. 
 Of persons with only a single risk factor of 
hypertension treatment, 39.3% showed the IGT pat-
tern.  These results indicated that FPG and HbA1c 
are effective enough to find DM, but FPG and 
HbA1c alone are insufficient to find IGT.  It is im-
portant to examine risk factors additional to hyper-
tension treatment.  In general, hypertension alone 
is not considered as a high-risk factor for abnormal 
glucose tolerance.  However, there are several re-
ports that hypertension is associated with the an-
giotensin II and aldosterone system, which affects 
insulin resistance (Folli et al., 1997; Sowers, 2004; 
Catena et al., 2006; Colussi et al., 2007).  Based 
on the present study, hypertension was a major 
risk factor for IGT.  These results are very interest-
ing from the view of novel IGT criteria.  Recently, 
the United States Preventive Services Task Force 
reported that evidence is lacking on the health ben-
efits of detecting type 2 diabetes by either targeted 
or mass screening, but persons with hypertension 
probably benefit from screening (Norris et al., 
2008).  According to the 2004 survey of hyperten-
sion treatment of Kofu Town, 289 patients had re-
ceived hypertension treatment:  216 patients (74.7%) 
used a calcium antagonist, 33 patients (11.4%) used 
an angiotensin-converting enzyme inhibitor, 163 
patients (56.4%) used an angiotension II receptor 
blocker, 113 patients (39.1%) used an alpha-blocker, 
17 patients (5.8%) used a beta-blocker and 63 pa-
tients (21.8%) used a diuretic (data not shown).  In 
the present study, we did not examine the preva-
lence of glucose intolerance according to the hy-
pertension drugs.  However, risk analysis by each 
drug would be a topic of future study.
 There are few reports describing criteria for 
screening IGT and DM in Japanese and Asian 
populations.  The criteria we presented here are a 
novel method to target early stages of IGT and DM 
in Japanese and Asian populations.  The Japanese 
Government plans to drop the FPG criteria from 6.1 
to 5.5 mmol/L (110 to 100 mg/dL), in order to find 
the early stage of diabetes and prevent the follow-
ing cardiovascular event.  Although the interpreta-
tion of this study is limited because of the small 
number of participants and no cohort study, this 
study supports such a new guideline for the Japa-
nese population and any other Asians.  Residents 
of Kofu Town have shown a high incidence of 
cerebral stroke.  According to NIPPON DATA80, 
which is an observation cohort study on stroke 
in the Japanese population, the stroke mortality 
tended to be almost 2 times higher in rural areas 
than in urban areas in Japan (Nishi et al., 2007). 
The mortality rate of stroke in rural areas is nearly 
equal to that of Kofu Town.  The reason for this 
geographical variation is likely to be related to the 
prevalence of hypertension.  This type of environ-
ment is similar to Kofu Town, so our criteria would 
be applicable to other rural areas in Japan. 
 In conclusion, we were able to detect early 
stages of abnormal glucose tolerance using com-
binations of FPG, HbA1c, BMI, triglyceride, hy-
pertension treatment and family history of DM. 
The results indicate that only FPG ≥ 6.1 mmol/L 
(110 mg/dL) is not sufficient to detect early stages 
of DM and IGT.  The most useful criteria for early 
detection of IGT and DM were FPG ≥ 5.2 mmol/
L (93 mg/dL) and HbA1c ≥ 5.3%.  In addition, even 
if FPG was less than 5.5 mmol/L (100 mg/dL), hy-
pertension treatment might be taken into account 
for the IGT risk, since 39.3% of persons with a 
single risk factor of hypertension treatment showed 
the IGT pattern.  The interpretation of this study 
was limited, since it was not a cohort study and the 
group of 220 OGTT-received residents was biased.
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